Tag: big pharma

Joe Rogan Stunned by Liberal Pregnant Women Downing Tylenol to Own Trump: ‘This Science Came From Harvard’

People have often joked that if Trump said breathing air is good for you, liberals would start dying of suffocation. Now we know there is some real truth behind that.

As the Gateway Pundit has reported, once the Trump administration cautioned pregnant women from taking Tylenol, pregnant liberal women started going on the internet and downing Tylenol, even filming it, in some cases with disastrous results.

On a recent episode of his podcast, Joe Rogan commented on this, noting that this science has been backed up by Harvard.

The Daily Caller reports:

Podcast host Joe Rogan on “The Joe Rogan Experience” Friday called out pregnant women who have been filming themselves consuming Tylenol in objection to President Donald Trump’s administration’s recommendation not to do so.

TikTok users ingested large amounts of Tylenol to mock Trump and Health and Human Services Secretary Robert F. Kennedy Jr. after announcing the findings of an association between the use of acetaminophen by pregnant women and autism diagnoses in children. Rogan noted on his podcast that the Trump administration cited a Harvard study to support its findings.

“I’ve been fascinated by these videos of pregnant women taking Tylenol to show Trump that they don’t believe in what RFK Jr. is saying, that it’s somehow or another anti-science — when this science came from Harvard,” Rogan said. “That’s where the study came from. He’s not making things up. And these people are like on TikTok — they’re pregnant women taking Tylenol.”

Keep reading

SCOOP: Tylenol Maker Privately Admitted Evidence Was Getting ‘Heavy’ For Autism Risk In 2018

The pharmaceutical company behind Tylenol privately acknowledged the likelihood of an association between its drug in pregnancy and neurodevelopmental disorders like autism in children seven years ago, company documents obtained by the Daily Caller News Foundation show.

“The weight of the evidence is starting to feel heavy to me,” said Rachel Weinstein, U.S. director of epidemiology for Janssen, the pharmaceutical arm of Johnson & Johnson, in 2018. Johnson & Johnson marketed Tylenol at the time but in 2023 spun off its consumer products division into a separate company called Kenvue.

Legacy media headlines and vocal public health experts have dismissed the conclusion of President Donald Trump and Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. that Tylenol taken in pregnancy and early infancy has driven rises in autism. But one stakeholder has for years viewed the evidence as credible enough to act upon, at least privately: The makers of Tylenol.

Keep reading

Government Announcement on Autism Should Revive Lawsuits Over Tylenol: Attorneys

The federal government’s new warning that taking Tylenol during pregnancy may lead to autism should prompt the revival of lawsuits from mothers who allege Tylenol caused their children’s autism or attention-deficit/hyperactivity disorder (ADHD), attorneys for the families said in a new filing.

Federal officials on Sept. 22 moved to update labeling for Tylenol and other drugs containing acetaminophen, which are used for pain and fever relief. Regulators said that “the use of acetaminophen by pregnant women may be associated with an increased risk of … autism and ADHD in children.”

During a press conference announcing the moves, Food and Drug Commissioner Dr. Marty Makary quoted Dr. Andrea Baccarelli, a dean at the Harvard School of Public Health, who said in his expert opinion in the legal case that “there is a causal relationship” between in utero exposure to acetaminophen and neurodevelopmental disorders such as autism.

“Expert opinion that is sound enough to persuade every Senate-confirmed federal scientist easily clears Rule 702(d)’s bar,” the attorneys said in the filing on Wednesday, referring to a rule governing the use of expert witnesses in litigation.

“Reasonable scientists can continue to debate Dr. Baccarelli’s conclusions. But affirming a decision characterizing his approach as ‘junk science’ would pose grave separation of powers concerns,” the attorneys said. “The executive branch safeguards public health from dangerous pharmaceutical interventions. A decision holding that a jury may not hear the same expert evidence that the executive branch credited will badly damage the public trust required for the executive to take care that the public-health laws are faithfully executed.”

The lawsuits in question alleged that retailers and Kenvue, which makes Tylenol, failed to warn people that drugs containing acetaminophen could cause autism or ADHD. U.S. District Judge Denise Cote ruled in 2023 that Baccarelli and other experts offered by plaintiffs cherry-picked and misrepresented the results of studies. She later dismissed the cases.

Keep reading

HHS Resurfaces Old Tylenol Post Warning Pregnant Women NOT to Use Their Product

The Department of Health and Human Services (HHS) resurfaced an eight-year-old tweet from Tylenol’s account.

The timing is ominous: the administration is now aggressively pushing a narrative linking Tylenol (acetaminophen) use in pregnancy to autism in children.

Just days ago, President Trump sounded the alarm on the potential link between Tylenol use during pregnancy and skyrocketing autism rates in children – a connection that’s been buried by the deep state bureaucrats at the FDA for far too long.

As reported by Bloomberg, HHS reposted the circa 2017 message on its official X account, with the chilling tag “No caption needed.”

The resurfaced statement from Tylenol’s official account bluntly told a concerned user:

“We actually don’t recommend using any of our products while pregnant. Thank you for taking the time to voice your concerns today.”

According to PBS, “Kenvue said in a statement that ‘sound science clearly shows that taking acetaminophen does not cause autism.” The company pointed to scientific reviews by multiple government regulators worldwide, including those previously published by the FDA.”

However in 2019, Tylenol also openly admitted: “It’d be great to touch base real quick since we haven’t tested Tylenol to be used during pregnancy (and see what coupons we have for baby!)”

Keep reading

Leavitt Torpedoes CBS Reporter’s Autism ‘Confusion’ Attack

In a sharp exchange during today’s White House briefing, Press Secretary Karoline Leavitt dismantled CBS News senior White House correspondent Ed O’Keefe’s attempt to frame President Trump’s upcoming autism announcement as potentially misleading for pregnant women.

O’Keefe pressed: “There are reams of scientific research that suggest there’s no clear link between autism and acetaminophen usage… [this] has the potential to confuse women, especially pregnant women, about what to do.”

Leavitt fired back without missing a beat: “I think women, for many years, in fact, for decades, Ed, have been confused by the rapid increase in autism in this country, in the childhood epidemic, that chronic epidemic, disease epidemic that is plaguing America’s youth.”

“Women are confused about that and they want answers to that,” Leavitt added, further noting “I would encourage everyone in this room to… listen to what the president and his team of outsiders have to say about this.”

The back-and-forth comes ahead of Trump’s 4 p.m. ET remarks, where he’s expected to highlight a potential link between prenatal acetaminophen use (the active ingredient in Tylenol) and rising autism rates—a claim already drawing fire from medical experts and the drug’s manufacturer, who cite large-scale studies showing no causal connection.

Leavitt’s pivot refocused the narrative on the administration’s push for answers to what she called a “chronic disease epidemic,” urging reporters to approach the announcement with “critical thinking skills and open ears.”

Spot-on clapback—Leavitt turned a gotcha question into a masterclass in redirecting to the bigger picture.

Tylenol’s parent company earlier commented on the upcoming announcement, stating “We believe independent, sound science clearly shows that taking acetaminophen does not cause autism. We strongly disagree with any suggestion otherwise and are deeply concerned with the health risk that this poses for expecting mothers.”

Keep reading

FDA Warns Companies Against False and Misleading Drug Ads

Federal regulators sent dozens of letters to companies in September warning them that their advertisements for drugs are misleading and could lead to repercussions unless fixed.

The Food and Drug Administration on Sept. 16 released 65 letters it sent on Sept. 9 to companies, including Eli Lilly and Novo Nordisk. President Donald Trump signed a memorandum that day directing officials to enforce existing rules surrounding direct-to-consumer advertising for drugs.

In letters to Eli Lilly, FDA officials said that advertisements for weight loss products, including one that originally appeared in a special held by Oprah Winfrey, did not present people with accurate information about possible side effects.

The ad that aired during the Oprah special “creates a misleading impression regarding the safety of Zepbound and Mounjaro, which are drugs with multiple serious, potentially life threatening risks,” officials with the FDA’s Center for Drug Evaluation and Research said in one of the letters. They said that people who seek medical treatment for obesity or Type 2 diabetes “should receive truthful and non-misleading information.”

An Eli Lilly spokesperson told The Epoch Times in an email: “FDA’s correspondence to Lilly addresses three interviews conducted by independent media outlets. These interviews were not advertisements, and Lilly had no editorial control over them.

“We remain committed to providing patients with accurate, reliable information that empowers them to make informed healthcare decisions in partnership with their physicians.”

Keep reading

FDA targets Hims & Hers, posts more than 100 letters to drugmakers

The Trump administration is cracking down on pharmaceutical advertising and they are specifically targeting telehealth companies that promote unofficial versions of weight loss medications.

More than 100 letters were posted by the Food and Drug Administration to drugmakers and online prescribing companies. Hims & Hers built a multibillion-dollar business around weight loss interventions. The letters warned the companies, including Hims & Hers, to remove “false and misleading ” promotional statements and advertising from their website.

Your claims imply that your products are the same as an FDA-approved product when they are not,” states the warning letter, dated Sept. 9.

Hims said Tuesday that it “looks forward to engaging with the FDA.”

“Our website and our customer-facing materials note that compounded treatments are not approved or evaluated by the FDA,” the company said in a statement.

Keep reading

Sweeping Trump crackdown on misleading pharmaceutical ads is first in nearly 3 decades

In a landmark move, the Trump administration has launched a sweeping crackdown on misleading pharmaceutical advertisements, the first major enforcement effort since direct-to-consumer drug ads were legalized in 1997. 

FDA Commissioner Dr. Marty Makary recently spoke with Full Measure about the unprecedented effort, stating that the agency is sending “thousands” of enforcement letters targeting deceptive promotions across TV, social media, and online platforms. 

The U.S. is one of only two countries allowing such ads (the other is New Zealand). Makary says the commercials often downplay serious risks, present false information, or mislead viewers by showcasing happy, dancing patients. He says FDA enforcement has been notoriously lax for decades, with FDA violation letters to drug companies dropping from 130 annually in the late 1990s to zero in 2024. 

The new plan targets not just TV but also social media influencers and online pharmacies. 

A key focus is closing the “adequate provision loophole,” which allowed vaccine ads to skip disclosing any risks at all by listing them elsewhere, like on websites. 

Makary argues this violates regulations against misleading impressions, and the FDA is moving to eliminate it.

No comparable crackdowns on misleading drug ads have ever been launched. Many observers say that’s in part due to the pharmaceutical industry’s influence with members of Congress who get big money from drug companies. They also blame inaction on the media that benefits from all the money drug ads bring in and make them more likely to defend the industry and downplay or censor prescription drug risks and concerns.

Keep reading

Trump cracks down on drug ads on TV, social media that he says mislead people

President Trump went after pharmaceutical companies Tuesday by accusing them of intentionally concealing dangerous side effects when marketing their drugs on TV and social media.

He sent roughly 100 cease and desist letters and thousands of warning letters to companies about their advertising.

He also granted broad authority to Health and Human Services Secretary Robert F. Kennedy Jr. and Food and Drug Administration Commissioner Marty Makary to rein in the companies and their social media influencers.

Among the measures pharmaceutical companies can take are increasing the amount of information about risks associated with the medicine in advertisements and actions to “ensure truthful and non-misleading information in direct-to-consumer prescription drug advertisements

The president hardened the government’s stance against Big Pharma with a proclamation he signed Tuesday in the Oval Office. He did not add new enforcement action but ordered the government to more stringently ramp up enforcement of existing regulations covering drug commercials.

“Our goal is to ensure that patients have proper information about drugs that have potential harms,” a senior administration official said. “I think people are seeing ads sometimes not even realizing that they’re pharmaceutical ads.”

The White House declined to say which companies or influencers would receive the letters, but the official referenced a weight loss drug commercial that ran during the Super Bowl and drew the ire of senators on both sides of the aisle.

Hims & Hers, a telehealth company, faced scrutiny from Sens. Richard J. Durbin, Illinois Democrat, and Roger Marshall, Kansas Republican, for an ad promoting the active ingredient in the weight loss drug Ozempic, but not the drug itself. The two senators said the TV ad “risks misleading patients by omitting any safety or side effect information.”

Under Federal Trade Commission guidelines, Hims & Hers did not have to provide side effect information because it did not advertise a specific drug or medication. Instead, it urged consumers to consult with a doctor, which was consistent with FTC regulations.

Drug advertising aimed at consumers has exploded since the FDA relaxed its policies in 1997. The loosening of restrictions allowed pharmaceutical companies to boast of health claims while disclosing only a drug’s “most important” health risks. Before the policy change, drug companies had to disclose a lengthy list of possible side effects or avoid identifying the purpose of the drug in the first place.

However, enforcement of those guidelines has slacked in recent years. The FDA typically sends roughly 100 letters yearly, taking drug companies to task for their advertising. However, in 2023, the FDA sent only one such letter and did not send any last year, according to the White House.

“There are also regulations that speak very clearly that an ad must present a fair balance of information … but despite these regulations, enforcement has been increasingly lax over recent years [compared with] in the past when ads were far less frequent,” the official said.

Prescription drug ads account for hundreds of billions of dollars in advertising dollars spent each year. Through this summer, prescription drug brands accounted for 24.4% of ad minutes across evening news programs on NBC, ABC, CBS, Fox News, MSNBC and CNN, according to data from iSpot, which tracks television advertising.

Keep reading

Audience ERUPTS as Vaccine Lawsuit Expert Aaron Siri TORCHES Democrat Sen. Blumenthal for Pathetic Attempt to Discredit Him — After Siri Exposes Buried Study Showing Vaccinated Kids Face SKYROCKETING Chronic Illness Compared to Unvaccinated Peers

The Senate Homeland Security and Governmental Affairs Committee held a bombshell hearing Tuesday afternoon on how the corruption of “science” has manipulated vaccine policy, public perception, and parents’ choices.

Attorney Aaron Siri, managing partner at Siri & Glimstad LLP, dropped a nuclear truth bomb on the vaccine establishment, exposing how the government, medical elites, and Big Pharma buried damning data proving vaccinated children face far higher rates of chronic illness than their unvaccinated peers.

Siri testified that none of the clinical trials relied upon to license routine childhood vaccines on the CDC’s schedule ever proved the products safe before licensure due to glaring design flaws.

Worse, post-licensure monitoring is riddled with manipulation and “a priori” assumptions that vaccines are inherently safe, effectively corrupting the entire scientific process.

According to Siri, a team of respected researchers at Henry Ford Health in Detroit, led by Dr. Marcus Zervos, Division Head of Infectious Disease, undertook a massive vaccinated vs. unvaccinated birth cohort study involving 18,468 children enrolled between 2000 and 2016.

The results were devastating to the vaccine establishment:

  • Vaccinated children were 3.03 times more likely to develop allergic diseases.
  • 4.29 times more likely to develop asthma.
  • 5.53 times more likely to suffer neurodevelopmental disorders — including speech disorders and developmental delays.
  • 5.96 times more likely to develop autoimmune diseases.
  • Not a single case of ADHD, learning disability, or tics was found among the unvaccinated, while hundreds of cases existed among the vaccinated cohort

By age 10, only 43% of vaccinated children remained free of chronic disease — compared to 83% of unvaccinated children

Despite the study being well-designed and internally validated, the researchers refused to publish it, fearing career destruction. Dr. Lois Lamerato admitted she “did not want to make doctors uncomfortable,” while Dr. Zervos feared losing his job.

Siri blasted this blatant cover-up, warning that if the results had shown vaccines improving health outcomes, the study would have been published immediately. Instead, because the findings threatened the pharmaceutical-government alliance, the study was buried, leaving parents in the dark.

Keep reading